Evidence map›Paper›PMID 33498782›Full record

ArticleJournal of clinical medicine2021

Ahlima Roumane, George D Mcilroy, Arda Balci, Weiping Han, Mirela Delibegović, Massimiliano Baldassarre, Philip Newsholme, Justin J Rochford

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. The Effect ofAnimals : an open access journal from MDPI · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 4 countries.

Ahlima RoumaneThe Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0001-6831-4426
George D McilroyThe Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0003-4230-4355
Arda BalciInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0003-1887-821X
Weiping HanLaboratory of Metabolic Medicine, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.
Mirela DelibegovićThe Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
Massimiliano BaldassarreInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0002-2498-4767
Philip NewsholmeCurtin Health Innovation Research Institute, School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0002-0500-6984
Justin J RochfordThe Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0002-5020-4939
University of Aberdeen · GBAgency for Science, Technology and Research · SGCurtin University · AU

Funding

British Heart Foundation PG/14/43/30889Diabetes UK 17/0005621Diabetes UK 18/0005884Horizon 2020 2016-726152-TYPHIMedical Research Council MR/L002620/1
6 · The paper itself

Abstract

Congenital Generalized Lipodystrophy type 2 (CGL2) is the most severe form of lipodystrophy and is caused by mutations in the

Indexed as

BSCL2congenital generalized lipodystrophyimmunitymacrophagesseipin

Identifiers

PMID33498782
PMCPMC7865406
OpenAlexW3125765774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.